Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
about
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisVEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideNew Findings on Breast Cancer Stem Cells: A ReviewRemodeling Components of the Tumor Microenvironment to Enhance Cancer TherapyDevelopment of targeted therapies in treatment of glioblastomaOptimal combination of antiangiogenic therapy for hepatocellular carcinomaCirculating glioma biomarkersMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialitySmall-molecule agonists of mammalian Diaphanous-related (mDia) formins reveal an effective glioblastoma anti-invasion strategy.Standard chemoradiation for glioblastoma results in progressive brain volume lossRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerImmune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.Development of a mathematical model to estimate intra-tumor oxygen concentrations through multi-parametric imaging.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsTargeting cellular and microenvironmental multidrug resistance.Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition.A theoretical framework for determining cerebral vascular function and heterogeneity from dynamic susceptibility contrast MRIAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Pathways to clinical CLARITY: volumetric analysis of irregular, soft, and heterogeneous tissues in development and diseaseThe role of mechanical forces in tumor growth and therapyThe impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Antiangiogenic therapy for glioblastoma: current status and future prospects.Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomasImproved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients.Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialLessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Modulation of the tumor vasculature and oxygenation to improve therapyRepeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.
P2860
Q26740812-56A5D99B-623A-44CC-A8E2-20156A3452B4Q26770678-EEA10657-3AC9-4832-B207-F8B112C86166Q26771894-3D61E41E-8D45-41FA-9631-E6C3F0BD7E5FQ26777144-5A0CC5CA-FF72-4A6C-BA5B-23FE7FF20E82Q26778787-4436941E-148E-4240-BCCB-3E33EB8D9787Q26799458-2884FDD9-CF0A-4568-89A4-029DBFE40627Q26830329-3CA96BE8-4A6F-461B-940A-46EEF2C485ECQ27025007-73E598EA-DCF6-46DD-80CB-F6B3543AC4F8Q27306686-B6BD16E0-8934-444F-B0DD-6184CB736EDBQ27348869-8BC69F8F-8BD7-435B-AE33-700C703C23B1Q28068654-7E40BAE8-6C1C-405D-97FB-4205FCA1876CQ30275254-AC9896E4-D538-45A5-A0CA-F2112320F239Q30300114-6B3232D4-B69D-4200-B360-824DACDB00D4Q30359059-8FA2748B-AD53-4384-B8B4-58FED422B319Q30399006-6753B147-A74C-4CB3-8E5F-20F5C9F4A964Q30651792-4320B3D0-5AB8-47EC-97EB-2BA898FB1BD3Q30708866-EDEAFA01-F704-47A9-AB0C-D43B180CA3A7Q30821877-7C3C1CB9-F56F-4EB4-9AB2-B13A64964411Q30847284-06EA65B9-5BF9-4CD0-804C-A2DBF2BDC5EFQ30907831-659945D3-7FA3-4945-A73B-78BBB69242FFQ30930526-3D90258A-96B4-49F5-A8D2-E34448945E68Q30938805-412F43F9-FF2E-487C-ADC8-5362F70E1F87Q33576750-56CEF69D-FB68-493A-A513-7588C57FC90AQ33602284-9EFCDFE3-0643-49BD-85EB-9B8F49ED2A2EQ33650400-2E61F2F7-7978-46B1-B715-A849B6DE345FQ33727635-530390EA-FB9B-4A10-84F6-DD7B67F087CEQ33770680-67107D8C-24F3-43DA-849E-579B7EE439F6Q33919006-629ABBD5-F5D5-4F52-AF62-3AC9B74B480CQ33942378-62538945-CD46-48AE-9625-A248882DDD58Q34293163-FBECF7B0-3EC6-491D-8E31-828012E5F352Q34523319-430439FF-D7AD-4063-A9AB-09D7BA02710AQ34807753-23DD61C8-6028-4007-AC49-8918AF055A68Q35062862-B0FA0DBB-2010-4919-8E04-1931EB9AEFCBQ35104052-03595579-8DF6-4E0E-901A-8B30E8BF0FD0Q35133246-AE811CCB-F192-4EB3-A1C0-CF7D56DCE2AAQ35802452-1C787BF8-C58E-4F37-98B3-39C162ACC2D0Q35815291-7283FE00-2B53-4FBC-98F5-ADAF1FF0C03BQ35895174-C2418342-F7EA-45FD-842A-F8B99DA426FDQ35920685-9919C3AC-3DCB-439D-BABF-C6C122A90069Q36054267-96B8A0BB-5622-4A3F-935F-56A4B05076F0
P2860
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Improved tumor oxygenation and ...... cediranib and chemoradiation.
@en
Improved tumor oxygenation and ...... cediranib and chemoradiation.
@nl
type
label
Improved tumor oxygenation and ...... cediranib and chemoradiation.
@en
Improved tumor oxygenation and ...... cediranib and chemoradiation.
@nl
prefLabel
Improved tumor oxygenation and ...... cediranib and chemoradiation.
@en
Improved tumor oxygenation and ...... cediranib and chemoradiation.
@nl
P2093
P2860
P50
P356
P1476
Improved tumor oxygenation and ...... r cediranib and chemoradiation
@en
P2093
A Greg Sorensen
A John Iafrate
Andrew S Chi
April F Eichler
Bruce R Rosen
Christine Lu-Emerson
Dan G Duda
Dominique Jennings
Elizabeth R Gerstner
Fred H Hochberg
P2860
P304
19059-19064
P356
10.1073/PNAS.1318022110
P407
P577
2013-11-04T00:00:00Z